Navigation Links
Metachromatic Leukodystrophy Therapeutics Clinical Trials Market Review H2 2014 Report Available at LifeScienceIndustryResearch.com
Date:7/27/2014

Dallas, TX (PRWEB) July 27, 2014

Metachromatic leukodystrophy (MLD, also called Arylsulfatase A deficiency) is a lysosomal storage disease which is commonly listed in the family of leukodystrophies as well as among the sphingolipidoses as it affects the metabolism of sphingolipids. Leukodystrophies affect the growth and/or development of myelin, the fatty covering which acts as an insulator around nerve fibers throughout the central and peripheral nervous systems. MLD involves cerebroside sulfate accumulation. Metachromatic leukodystrophy, like most enzyme deficiencies, has an autosomal recessive inheritance pattern.

Complete Report Details @ http://www.lifescienceindustryresearch.com/metachromatic-leukodystrophy-mld-global-clinical-trials-review-h2-2014.html.

Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trial:

  •     Prominent Drugs
  •     Shire Plc
  •     The Cooper Companies, Inc.
  •     GlaxoSmithKline plc
  •     Cytomedix, Inc.

Clinical Trial Overview of Top Institutes / Government:

  •     University of Louisville
  •     IRCCS San Raffaele Milano
  •     Fondazione San Raffaele del Monte Tabor
  •     University of Rostock
  •     Fairview University Medical Center
  •     New York Medical College
  •     Masonic Cancer Center
  •     Institut National de la Sante et de la Recherche Medicale
  •     National Center for Research Resources

Order a purchase copy @ http://www.lifescienceindustryresearch.com/purchase?rname=18460.

“Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014? provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD).

Scope

  •     Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  •     Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  •     Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  •     Understand the dynamics of a particular indication in a condensed manner
  •     Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  •     Obtain discontinued trial listing for trials across the globe
  •     Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Inquire before Buying @ http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=18460 .

List of Tables
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 10
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 15
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 18
Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2014* 20
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 21
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 22
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 23
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Suspended Clinical Trials, 2014* 24
Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Terminated Clinical Trials, 2014* 25
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 26
Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 27
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 28
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 29
Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 30

Explore more reports on Pharmaceuticals industry at http://www.lifescienceindustryresearch.com/category/pharmaceuticals.

About Us:
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.

Read the full story at http://www.prweb.com/releases/2014-global-metachromatic/leukodystrophy-review/prweb12047502.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. The Ludwig Institute for Cancer Research announces launch of iTeos Therapeutics SA
3. FORMA Therapeutics teams with TGen Drug Development
4. Media alert: 24th EORTC - NCI - AACR Symposium Molecular Targets and Cancer Therapeutics
5. Research shows potential of microneedles to target therapeutics to the back of the eye
6. Cancer vaccine Special Focus series published in Human Vaccines & Immunotherapeutics
7. Scientist receives $2.8 Million to study cell signaling mechanism and develop potential therapeutics
8. Ontario Genomics Institute invests in stem cell technology at Tissue Regenerative Therapeutics
9. Liver Diseases Therapeutics Market - New Industry Research Report Published by Transparency Market Research
10. Global Peptide Therapeutics Market - New Market Research Report Published by Transparency Market Research
11. Corena Therapeutics Launched Coresatin, a Nonsteroidal Cream Used to Treat Critical Skin Conditions and Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for ... $12 an hour by 2020 and then adjusting it yearly to increase at the same ... wage, assure the wage floor does not erode again, and make future increases more predictable. ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm ... sciences executive with extensive sequencing and genomics experience, as Vice President of North American ... Hill will be responsible for leading the sales team in the commercialization of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, ... (iPS) cells and other difficult to transfect cells, announces its launch of the ... G9™ Gene Editing System is a complete system for culturing and transfecting ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology: